CAMP4 Therapeutics Corporation (CAMP)
Nasdaq: CAMP · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2018
Who owns CAMP4 Therapeutics Corporation
As filed with the SECHolders of 5% or more
7
Janus Henderson Group PLC holds 12.2% of Common Stock, as its SCHEDULE 13G filed Jan 8, 2026 says.
Directors and officers
11
report now, of 17 people on the record since 2024. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 7 named at left.
Holders of 5% or moreshare of the class, as filed
Janus Henderson Group PLC
SCHEDULE 13G · filed Jan 8, 2026 · Common Stock
Coastlands Capital LP
SCHEDULE 13G/A · filed Dec 11, 2025 · Common stock, par value $0.0001 per share · 10% in Sep 16, 2025
Andrew J. Schwab
SCHEDULE 13D/A · filed Aug 31, 2026 · Common Stock · 9.9% in Aug 5, 2026
Fmr LLC
SCHEDULE 13G/A · filed Feb 5, 2026 · COMMON STOCK · 6.7% in Nov 7, 2025
Vivo Opportunity Fund Holdings, L.P.
SCHEDULE 13G/A · filed Feb 13, 2026 · Common Stock, par value $0.0001 per share · 7.6% in Sep 17, 2025
Amir Nashat
SCHEDULE 13D/A · filed Aug 19, 2026 · Common Stock, par value $0.0001 per share · 8.4% in Sep 11, 2025
Trails Edge Capital Partners, LP
SCHEDULE 13G · filed Aug 10, 2026 · Common Stock, $0.0001 par value per share
Balyasny Asset Management L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock · reported falling below 5%, from 5.07% in May 15, 2026
Enavate Sciences GP, LLC
SCHEDULE 13D/A · filed Mar 11, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 6% in Dec 23, 2025
Michael P. Rubin
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
Marc L. Andreessen
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
HarbourVest Partners L.P.
SCHEDULE 13G/A · filed Oct 1, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 6.3% in May 14, 2025
What CAMP reports owning in othersstakes of 5% or more, and other ties
CAMP4 Therapeutics Corporation reports no stake in another company in the record.
Insider tradesForm 4
6sales
5purchases
0sales on a scheduled plan
2people selling
$2.5Msold, in dollars
$100,000bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window6 of 37 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Schwab Andrew J. | director | 5 | $2.5M | 0 | 0 | $0 |
| Gold Kelly | Chief Financial Officer | 0 | $0 | 0 | 2 | $100,000 |
| Mandel-Brehm Josh | Chief Executive Officer | 0 | $0 | 0 | 1 | $0 |
| Maricich Yuri | Chief Medical Officer | 0 | $0 | 0 | 1 | $0 |
| Young Richard A | director | 0 | $0 | 0 | 1 | $0 |
| Tardiff Daniel | Chief Scientific Officer | 1 | $0 | 0 | 0 | $0 |